Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +37.44%
#3 Glidr Glidr +35.94%
#4 Humanity Humanity +25.03%
#5 Tutorial Tutorial +21.66%
#6 Enso Enso +21.56%
#7 Codatta Codatta +19.97%
#8 Walrus Walrus +19.47%
#9 BOOK OF MEME BOOK OF MEME +18.59%
#10 Ribbita by Virtuals Ribbita by Virtuals +13.44%
Coin of the day
EXOD EXOD
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
Clasificación en acciones #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
Precio por acción
$0.6
Última sincronización: 2024-08-14
Capitalización bursátil
$2.09M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
SG
Comercio ASLAN Pharmaceuticals Limited (ASLN)

Categoría

Healthcare
Ingresos de ASLAN Pharmaceuticals Limited (ASLN)
Ingresos en Mar 2024 TTM: $12.00M
Según los últimos informes financieros de ASLAN Pharmaceuticals Limited, los ingresos actuales de la empresa (TTM) son $12.00M. En 2022, la empresa obtuvo unos ingresos de 0.00 igual a los ingresos del año 2021, que fueron de 0.00. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de ASLAN Pharmaceuticals Limited desde 2014 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
2026 (TTM) $12.00M 0.00%
2023 $12.00M 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 -100.00%
2019 $3.00M 0.00%
2018 0.00 0.00%
2017 0.00 -100.00%
2016 $11.49M 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 105,102.50%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 50,077.39%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 84,156.56%
BE